Facile Therapeutics
Marc Navre has an extensive background in the pharmaceutical and biotechnology industry. Currently serving as Sr. Vice President, Biology at Structure Therapeutics, Marc has held various leadership roles in companies such as Wemberly Scientific, Facile Therapeutics, Ardelyx, Catalyst Biosciences, Takeda San Diego, Affymax Research Institute, and Syntex. With a strong track record in drug discovery and development, Marc has been instrumental in the creation and management of biology platforms, as well as the development of innovative drug candidates. A graduate from the University of California, Berkeley, Marc's expertise lies in next-generation structure-based drug discovery, with a focus on challenging protein targets.
This person is not in any offices
Facile Therapeutics
Facile Therapeutics is bringing Ebselen into the clinic to demonstrate it will be effective in preventing the recurrence of CDI in a Proof-of-Concept (PoC) clinical trial.